Kriya Therapeutics has 6 close competitors: BioLinq, Calyxo, Egenesis.
Sector, valuation and status for each competitor.
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
BioLinqCalyxoEgenesisAbridgeBiopharmaceutical company developing gene therapy treatments for retinal and neurological diseases.
Kriya Therapeutics competes with 6 companies here: BioLinq, Calyxo, Egenesis, Redcliffe Lifetech, Abridge, Alloy Therapeutics.
Kriya Therapeutics was last valued at $200M (Jan 2021). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
Lead investors for each round are in the funding timeline.
The closest gene therapy and biotech peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Kriya Therapeutics is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
